Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
AIMS: Elevated non-fasting triglycerides mark elevated levels of remnant cholesterol. Using a Mendelian randomization approach, we tested whether genetically increased remnant cholesterol in hypertriglyceridaemia due to genetic variation in the apolipoprotein A5 gene (APOA5) associates with an increased risk of myocardial infarction (MI). METHODS AND RESULTS: We resequenced the core promoter and coding regions of APOA5 in individuals with the lowest 1% (n = 95) and highest 2% (n = 190) triglyceride levels in the Copenhagen City Heart Study (CCHS, n = 10 391). Genetic variants which differed in frequency between the two extreme triglyceride groups (c.-1131T > C, S19W, and c.*31C > T; P-value: 0.06 to <0.001), thus suggesting an effect on triglyceride levels, were genotyped in the Copenhagen General Population Study (CGPS), the CCHS, and the Copenhagen Ischemic Heart Disease Study (CIHDS), comprising a total of 5705 MI cases and 54 408 controls. Genotype combinations of these common variants associated with increases in non-fasting triglycerides and calculated remnant cholesterol of, respectively, up to 68% (1.10 mmol/L) and 56% (0.40 mmol/L) (P < 0.001), and with a corresponding odds ratio for MI of 1.87 (95% confidence interval: 1.25-2.81). Using APOA5 genotypes in instrumental variable analysis, the observational hazard ratio for a doubling in non-fasting triglycerides was 1.57 (1.32-2.68) compared with a causal genetic odds ratio of 1.94 (1.40-1.85) (P for comparison = 0.28). For calculated remnant cholesterol, the corresponding values were 1.67(1.38-2.02) observational and 2.23(1.48-3.35) causal (P for comparison = 0.21). CONCLUSION: These data are consistent with a causal association between elevated levels of remnant cholesterol in hypertriglyceridaemia and an increased risk of MI. Limitations include that remnants were not measured directly, and that APOA5 genetic variants may influence other lipoprotein parameters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [62]
In the citing paper
“Epidemiological and Mendelian randomization studies have also pointed toward a causal role of elevated triglycerides in atherosclerosis due to an elevation of remnant cholesterol particles (7-9).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Elevated triglycerides are associated with an increase in remnant cholesterol, a decrease in high-density lipoprotein cholesterol (HDL-C), and an increase in LDL particles with a change in morphology to small, dense particles.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Recent systematic studies comparing fasting and non-fasting samples have suggested that the difference is small for most lipid parameters [85,94-100].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [94]
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [76]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 1×
“Causal genetic estimates from instrumental variable analysis were compared with an observed risk of MI from observational epidemiology using the Altman and Bland method.(29)”
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Research works printed but not linked: 1
- 2001, Type III hyperlipoproteinemia (dyslipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 2835
Cited by
Items 301–400 of 506
Ko, Y., Hsu, L., Wu, S., Liao, M.-S., Teng, M., Chou, H., & Ko, Y. (2025) · Genes · doi:10.3390/genes16020157 · Cited by 9
Association between RC/HDL-C and hyperuricemia in adults: evidence from NHANES 2005-2018
Tai, Y., Chen, B., Kong, Y., & Wang, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1514067 · Cited by 8
Not all fibrates are made equal: Learning from biology and clinical trials
Zambon, A., Staels, B., Farnier, M., Vrablík, M., & Catapano, A. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120555 · Cited by 8
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides
Pareek, M., Mason, R. P., & Bhatt, D. L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1954158 · Cited by 9
Tian, Y., Wu, W., Li, Q., Yu, X., Cai, L., Wang, H., & Zhang, Z. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.951523 · Cited by 8
Toth, P. P., Ferrières, J., Waters, M., Mortensen, M. B., Lan, N. S. R., & Wong, N. D. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1220017 · Cited by 9
Elahimanesh, M., Shokri, N., Mahdinia, E., Mohammadi, P., Parvaz, N., & Najafi, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-54086-w · Cited by 9
Zhang, L., Du, J., Guo, Q., Xu, X., Li, H., Zhong, N., Zhang, J., Li, G., & Shao, B. (2024) · Food and Chemical Toxicology · doi:10.1016/j.fct.2024.115066 · Cited by 10
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
Self-citationAl-Sabti, H. A., Al-Hinai, A. T., Al-Zakwani, I. S., Al-Hashmi, K., Almahmeed, W. A., Arafah, M., Shehab, A. M., Tamimi, O. A., Alawadhi, M., Herz, S. A., et al. (2022) · Oman Medical Journal · doi:10.5001/omj.2022.79 · Cited by 9
Yang, P., Tang, L. P., Yang, S., Shi, Q., Wang, Y., Qin, Y., Wang, J., & Li, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-59173-6 · Cited by 7
Triglycerides and T Cells in Cardiovascular Risk
Reilly, N. A., Mulder, J. W. C. M., Dekkers, K. F., Kuipers, T. B., der Zee, L. C. V. V., Mulder, M. T., van Lennep, J. E. R., Jukema, J. W., & Heijmans, B. T. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101359 · Cited by 7
Aterogénica, P. E. D. E. V. E. D. G. D. T. S. D. (2016) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.12.001 · Cited by 11
Engell, A. E., Bathum, L., Siersma, V., Andersen, C. L., Lind, B., & Jørgensen, H. L. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02607-5 · Cited by 7
Kim, M., Yoo, H. J., Lee, H. J., & Lee, J. H. (2018) · Hypertension Research · doi:10.1038/s41440-018-0137-y · Cited by 7
Woo, J. S., Hong, S. J., Hoon, D., Kim, K. S., Kim, M. H., Lee, J., Jeong, M. H., Jeong, J., Lee, J.-H., Jeon, D. S., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.001 · Cited by 9
Lipoprotein remnants: to be or not to be
Pirillo, A., & Catapano, A. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab511 · Cited by 7
Xie, X., Li, X., Li, H., Gao, Y., Zhao, F., & Chen, J. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1642358 · Cited by 7
Li, Y., Chen, P., & Gao, B. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02820-2 · Cited by 8
Du, Z., Wang, S., Yang, O., He, J., Yang, Y., Zheng, J., Zhao, H., & Cai, Y. (2024) · Health Information Science and Systems · doi:10.1007/s13755-024-00310-w · Cited by 7
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70005 · Cited by 6
Self-citationMultilayer regulation of postprandial triglyceride metabolism in response to acute cold exposure
Zhang, Y., Zhou, S., Zhao, R., Xiong, C., Huang, Y., Zhang, M., & Wang, Y. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100751 · Cited by 6
Hvid, K., Balling, M., Nordestgaard, B. G., & Afzal, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf735 · Cited by 7
Self-citationKim, J. D., Hwang, Y., Ahn, H. Y., & Park, C. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.5.975 · Cited by 6
Rodríguez-Gutiérrez, P. G., Fausto, A. G. C., Zepeda-Olmos, P. M., Hernández-Flores, T. D. J., González-García, J. R., & Magaña‐Torres, M. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010465 · Cited by 7
Energy metabolism disorder dictates chronic hypoxia damage in heart defect with tetralogy of fallot
Liu, L., Huang, L., Yao, L., Zou, F., He, J., Zhao, X., Mei, L., & Huang, S. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1096664 · Cited by 6
Song, Y., Yang, J., Zhao, Q., Bai, Y., & Ruan, L. (2023) · Cerebrovascular Diseases · doi:10.1159/000527704 · Cited by 6
Xu, J. Q., Zhu, L., Xie, Y., Zhang, M., Xiao, Z., Su, R., Wen, T., & Liu, L. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230328110215 · Cited by 7
Wang, A., Tian, X., Xie, X., Li, H., Jing, J., Lin, J., Wang, Y., Zhao, X., Li, Z., Liu, L., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102357 · Cited by 6
Wang, Z., Zhong, S., Wu, M., Shao, X., Gu, T., Xu, M., & Yang, Q.-C. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2357-2579 · Cited by 6
Feng, X., Liu, Y., Yang, J., Zhou, Z., Yang, S., Zhou, Y., & Guo, Q. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02258-y · Cited by 6
Verbeek, R., Oldoni, F., Surendran, R. P., Zwinderman, A. H., Khaw, K., Stroes, E. S. G., Wareham, N. J., Boekholdt, S. M., & Dallinga‐Thie, G. M. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.02.005 · Cited by 8
Wang, A., Tian, X., Zuo, Y., Wu, J., Tang, H., Wang, Y., & Zhao, X. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.10.002 · Cited by 6
Bai, M., Liao, J., Wang, Y., Liang, M., Wang, C., Zhang, J., & Shao, M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1417228 · Cited by 6
Tada, H., Kawashiri, M., Nohara, A., Inazu, A., Mabuchi, H., Yamagishi, M., & Hayashi, K. (2015) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2015.03.001 · Cited by 6
Silva, A. M. E., Aguíar, C., Duarte, J. S., Couto, L., Veríssimo, M. T., & da Silva, P. M. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.03.005 · Cited by 9
Liu, S., Fang, F., & Fan, G.-H. (2019) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2019.12.05 · Cited by 6
Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki, K. C., & Dicklin, M. R. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000741 · Cited by 6
Choe, H. J., Park, S. H., Han, K., Moon, M. K., & Koo, B. K. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.11.008 · Cited by 7
Chailurkit, L., Aekplakorn, W., Srijaruskul, K., & Ongphiphadhanakul, B. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0333-1 · Cited by 6
Zhao, J., Mei, Y., Li, A., Zhou, Q., Zhao, M., Xu, J., Li, Y., Li, Y., Yang, M., & Xu, Q. (2024) · Chemosphere · doi:10.1016/j.chemosphere.2024.142251 · Cited by 5
Nsiah, P., Acquah, S., Bockarie, A. S., Adjei, G., Aniakwaa-Bonsu, E., & Debrah, O. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1551203 · Cited by 5
Cui, L., Liu, C., Yang, L., Liang, J., Wang, H., Liu, C., Zhang, F., & Cao, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-09678-5 · Cited by 6
Nordestgaard, L. T., Luo, J., Emanuelsson, F., Leyden, G. M., Sanderson, E. C. M., Smith, G. D., Christoffersen, M., Afzal, S., Benn, M., Nordestgaard, B. G., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf662 · Cited by 6
Self-citationRemnant cholesterol and cardiovascular and all-cause mortality in Korean adults
Kim, B. J., Lee, M. Y., Cho, E. H., Jang, A. Y., & Kang, J. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.014 · Cited by 5
Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk
Bharadiya, V. M., Rawal, S., Jain, V., Chevli, P. A., & Mehta, A. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00702-1 · Cited by 5
Du, X., Ding, J., Ma, X., Yang, R., Wang, L., & Sha, D. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02957-0 · Cited by 7
Lipids and cardiovascular disease 3 Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · Cited by 5
Self-citationChan, D. C., Pang, J., & Watts, G. F. (2015) · Springer eBooks · doi:10.1007/978-3-319-12125-3_30-1 · Cited by 7
ESC-Leitlinien 2016 – Dyslipidämien
Sinning, D., & Landmesser, U. (2016) · Herz · doi:10.1007/s00059-016-4505-6 · Cited by 8
Boden, W. E., & Andersson, C. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.001 · Cited by 5
Pechlaner, R., Friedrich, N., Staudt, A., Gande, N., Bernar, B., Stock, K., Zollner-Kiechl, S., Hochmayr, C., Griesmacher, A., Petersmann, A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.12.007 · Cited by 4
Hipertrigliceridemia (> 150 mg/dl) como marcador de riesgo cardiovascular
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500822 · Cited by 4
Guo, L., Zhu, L., Xu, J. R., Xie, Y., Xiang, Q., Jiang, Z.-Y., Tan, Y., & Liu, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.736059 · Cited by 4
Bian, X., Zhang, Y., Shao, M., Li, J., Ge, J., Li, Z., Peng, H. Y., & Zhang, M. (2024) · Coronary Artery Disease · doi:10.1097/mca.0000000000001361 · Cited by 6
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Peng, Y., Chen, G., & Zheng, H. (2020) · PubMed Central · doi:10.12122/j.issn.1673-4254.2020.08.11 · Cited by 6
Blauw, L. L., Noordam, R., van der Laan, S. W., Trompet, S., Kooijman, S., van Heemst, D., Jukema, J. W., van Setten, J., de Borst, G. J., Tybjærg‐Hansen, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10050932 · Cited by 5
Self-citationFellow's voice: Hypertriglyceridemia: Understanding the current guideline
Koneru, S. C. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100322 · Cited by 4
Fatica, E. M., Jenkins, S. M., Scott, R. J., Block, D. R., Meeusen, J. W., Baumann, N. A., Saenger, A. K., & Donato, L. J. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfac039 · Cited by 4
Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review
Sutariya, B., Montenegro, D. M., Chukwu, M., Ehsan, P., Aburumman, R. N., Muthanna, S. I., Menon, S. R., Vithani, V., & Penumetcha, S. S. (2022) · Cureus · doi:10.7759/cureus.32346 · Cited by 5
Salehi, S., Emadi‐Baygi, M., Rezaei, M., Kelishadi, R., & Nikpour, P. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.42.1.74 · Cited by 4
Varbo, A., Langsted, A., & Nordestgaard, B. G. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw215 · Cited by 5
Self-citationLin, L., Lin, J., Yan, J., & Wang, X. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04172 · Cited by 3
Pitaro, N. L., Bay, B., Sartori, S., Vogel, B., Gitto, M., Smith, K. F., Feng, Y., Muro, F. M. D., Oliva, A., Nicolas, J., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf683 · Cited by 4
Bubnova, M. G., Ezhov, M. N., Aronov, D. M., Galyavich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6364 · Cited by 6
Ren, X., Tian, Y., Tian, J., Wang, G., & Liu, J. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113030 · Cited by 4
Lu, F., & Yang, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113190 · Cited by 4
Lan, Y., Guo, Z., Dai, J., Chen, K., & Chen, Y. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.03.013 · Cited by 3
Yu, C., Wang, T., Zhu, L., Zhou, W., Bao, H., & Cheng, X. (2025) · BMC Public Health · doi:10.1186/s12889-025-24635-7 · Cited by 3
Atherogenic dyslipidaemia in type 2 diabetes mellitus: The PREDISAT study
Climent, E., Millán, J., Ascaso, J. F., Tembra, M. S., Morillas, C., Civeira, F., Bellón, J. M., Pedro‐Botet, J., & the Spanish Atherosclerosis Society Working Group on Atherogenic Dyslipidaemia (2023) · Lipids · doi:10.1002/lipd.12374 · Cited by 3
Remnant cholesterol and suicide attempts in untreated first-episode major depressive disorder
Xu, P., Fan, C., Yan, M., Liu, J., & Zhang, X. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1493509 · Cited by 4
Lüscher, T. F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv049 · Cited by 3
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Nordestgaard, B. G., & Varbo, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_8 · Cited by 4
Self-citationInfluence of remnant cholesterol levels on carotid intima thickness in type 2 diabetes patients
Liu, R., Xu, T., Gan, L., Chang, C., Peng, Y., Yao, W., Zhai, A., Fang, M., Shang, X., Chang, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71780-x · Cited by 2
Leiviskä, J., Sundvall, J., Jauhiainen, M., Kotseva, K., Tuomilehto, J., Backer, G. D., Tokgözoğlu, L. S., Reiner, Ž., & Bacquer, D. D. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120653 · Cited by 2
Wu, X., Wu, M., Huang, H., Liu, Z., Huang, H., & Wang, L. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1651935 · Cited by 3
Zhang, J., Wang, Z.-X., Wang, Q.-Q., Liu, Y., Shao, Q., Pan, Y., & Zhong, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1651416 · Cited by 3
Muñiz, Á. M., López‐Melgar, B., Raposo‐López, J. J., Navas-Moreno, V., Cecconi, A., Caballero, P., Hernández, S., de Benavides, C., Marazuela, M., Borreguero, L. J. J., et al. (2025) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2025.12.006 · Cited by 3
Association of Remnant Cholesterol With Self‑Reported Trouble Sleeping and Mediation by Depression
Yang, Q., Wang, Z., Yan, H., & Shao, X. (2026) · Brain and Behavior · doi:10.1002/brb3.71201 · Cited by 2
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Self-citationNordestgaard, A. G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01393-4 · Cited by 3
Byrne, P., Lin, T., Jones, M., Demasi, M., Saif-Ur-Rahman, K., & DuBroff, R. J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.026 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Yang, G., Lei, M.-M., Yu, C.-L., Liu, X.-X., An, Z., & Song, C.-L. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0110-6 · Cited by 2
Does lowering triglycerides reduce cardiovascular risk?
de Moura, J. P. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.10.001 · Cited by 2
Tan, Y., Lin, Q., Xu, J. R., Zhu, L., Guo, L., Xie, Y., Du, X., Zhang, S., Wen, T., & Liu, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.799300 · Cited by 2
Kaltoft, M., Langsted, A., & Nordestgaard, B. G. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2022.2.e20 · Cited by 2
Self-citationAntequera-González, B., Faiges, M., Martínez-Micaelo, N., Galián-Gay, L., Ligero, C., Vallverdú, M. F., Masana, L., Amigó, N., Evangelista, A., & Alegret, J. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010332 · Cited by 2
Xie, Y., Guo, L., Chen, H., Xu, J. R., Qu, P., Zhu, L., Tan, Y., Zhang, M., Wen, T., & Liu, L. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1037270 · Cited by 2
Hu, X., Lin, Y., Appleton, A. A., Wang, W., Yu, B., Zhou, L., Li, G., Zhou, Y., Ou, Y., & Dong, H. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01304-0 · Cited by 2
Huang, X., Sun, T., Zhang, B., Ma, M., Chen, Z., Zhao, Z., Dong, S., & Zhou, Y. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2458200 · Cited by 2
de Assis, A. C. R., Rezende, P. C., Hueb, W. A., Neto, A. S., Scudeler, T. L., Garcia, R. M. R., Andrade, V. C., da Silva, M. F., Ribeiro, M. D. O. L., Mocha, M. R., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf192 · Cited by 3
Jian, G., Jiang, K., Lu, Z., He, S., Xie, L., Zhang, S., Wang, Q., Lu, H., Xiong, Z., Wu, Z., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1624112 · Cited by 2
Cardiovascular Risk Assessment in Patients with Hypertriglyceridemia
Evans, M. C., Stalam, T., & Miller, M. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1013-8 · Cited by 2
Silva, A. M. E., Aguíar, C., Duarte, J. S., Couto, L., Veríssimo, M. T., & da Silva, P. M. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.03.010 · Cited by 4
Kumar, A. H. S., & George, M. (2020) · Biology Engineering Medicine and Science Reports · doi:10.5530/bems.5.2.9 · Cited by 2
Pathogenesis of atherosclerosis: lipid metabolism
Wiklund, O., & Borén, J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198755777.003.0011 · Cited by 3
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-17
- Volume
- 34
- Issue
- 24
- Pages
- 1826-1833
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2040770080
- Cited by
- 501
- References
- 60
- Citations by year
- 2026: 28 · 2025: 53 · 2024: 48 · 2023: 40 · 2022: 51 · 2021: 45 · 2020: 41 · 2019: 39 · 2018: 26 · 2017: 34 · 2016: 31 · 2015: 30 · 2014: 20 · 2013: 11
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- remnant cholesterol, hypertriglyceridemia, myocardial infarction, APOA5, genetic variants, causal risk factors, remnant lipoproteins, Copenhagen City Heart Study, Copenhagen General Population Study, instrumental variables, Mendelian randomization
- MeSH terms
- Apolipoprotein A-V, Adult, Aged, Aged, 80 and over, Apolipoproteins A, Cholesterol, Female, Genotype, Humans, Lipoproteins, Male, Middle Aged, Myocardial Infarction, Promoter Regions, Genetic, Prospective Studies, Risk Factors, Triglycerides, Hypertriglyceridemia, Linkage Disequilibrium, Case-Control Studies, Polymorphism, Single Nucleotide, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.